NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novo Nordisk A/S (CO: NOVO-B)

 
NOVO-B Technical Analysis
5
As on 21st Nov 2024 NOVO-B STOCK Price closed @ 721.80 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 875.46 & Strong Sell for SHORT-TERM with Stoploss of 1133.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVO-BSTOCK Price

Open 733.20 Change Price %
High 742.00 1 Day -16.30 -2.21
Low 718.50 1 Week -27.10 -3.62
Close 721.80 1 Month -80.70 -10.06
Volume 2864199 1 Year -382.60 -34.64
52 Week High 1367.80 | 52 Week Low 625.70
 
CO Denmark Most Active Stocks
SAS 0.01 0.00%
CONFRZ 0.01 0.00%
NOVO-B 721.80 -2.21%
VWS 99.26 -1.72%
ASTRLS 1.15 8.49%
AGF-B 0.71 1.43%
BLVIS-A 0.40 -18.37%
DANSKE 203.50 -0.83%
ALMB 13.44 1.13%
ISS 126.20 -0.86%
 
CO Denmark Top Gainers Stocks
HYPE 3.66 22.00%
MAPS 1.59 21.37%
MAPS 1.59 21.37%
MAPS 1.59 21.37%
MAPS 1.59 21.37%
LEDIBOND 0.36 16.13%
DKIEEU 249.00 15.81%
GREENM 31.70 13.21%
SAME 1.45 10.69%
SAME 1.45 10.69%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
HYDRCT 0.24 -20.00%
BLVIS-A 0.40 -18.37%
STENO 2.18 -14.17%
HAPPY 0.18 -10.00%
SCAPE 0.11 -8.33%
GABR 212.00 -7.02%
MONSO 0.45 -6.25%
CBRAIN 196.80 -5.16%
TRMD-A 154.90 -5.14%
 
 
NOVO-B
Daily Charts
NOVO-B
Intraday Charts
Whats New @
Bazaartrend
NOVO-B
Free Analysis
 
NOVO-B Important Levels Intraday
RESISTANCE767.08
RESISTANCE752.56
RESISTANCE743.58
RESISTANCE734.61
SUPPORT708.99
SUPPORT700.02
SUPPORT691.04
SUPPORT676.52
 
NOVO-B Forecast November 2024
4th UP Forecast1243.25
3rd UP Forecast1076.02
2nd UP Forecast972.65
1st UP Forecast869.28
1st DOWN Forecast574.32
2nd DOWN Forecast470.95
3rd DOWN Forecast367.58
4th DOWN Forecast200.35
 
NOVO-B Weekly Forecast
4th UP Forecast844.36
3rd UP Forecast805.05
2nd UP Forecast780.76
1st UP Forecast756.46
1st DOWN Forecast687.14
2nd DOWN Forecast662.84
3rd DOWN Forecast638.55
4th DOWN Forecast599.24
 
NOVO-B Forecast2024
4th UP Forecast2198.46
3rd UP Forecast1724.89
2nd UP Forecast1432.16
1st UP Forecast1139.43
1st DOWN Forecast304.17
2nd DOWN Forecast11.44
3rd DOWN Forecast-281.29
4th DOWN Forecast-754.86
 
 
NOVO-B Other Details
Segment EQ
Market Capital 1565371138048.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
NOVO-B Address
NOVO-B
 
NOVO-B Latest News
 
Your Comments and Response on Novo Nordisk A/S
 
NOVO-B Business Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Allé 1, Bagsvaerd, Denmark, 2880
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service